Alpha-synuclein PET: works for MSA, not for Parkinson's
Parkinson's disease is defined by a protein clumping in the brain, and no scan can see it. The first tracer to reach patients does light up a rarer, related disease but not Parkinson's itself, while a spinal-fluid test already identifies Parkinson's with high accuracy.
Overview
Amyloid and tau both have approved PET agents. Alpha-synuclein, the protein that defines Parkinson's disease, dementia with Lewy bodies and multiple system atrophy, has none: no small molecule targeting misfolded alpha-synuclein has been approved by the FDA as a PET radiopharmaceutical. The clinical consequence is that early Parkinson's cannot be separated from multiple system atrophy or progressive supranuclear palsy when the picture is ambiguous, and no anti-alpha-synuclein drug programme can show target engagement in a living brain.
The most advanced agent is [18F]ACI-12589 from AC Immune, with a 42-participant published dataset in Nature Communications in 2023: 8 healthy controls, 8 Parkinson's, 2 dementia with Lewy bodies, 13 multiple system atrophy, 3 progressive supranuclear palsy, 5 Alzheimer's and 3 hereditary ataxias. The result is a genuine partial success and a genuine partial failure. Binding statistically separated multiple system atrophy patients from controls and from other neurodegenerative disorders, with clear signal in cerebellar white matter and middle cerebellar peduncles, but limited binding in Parkinson's disease; a conference report put it more bluntly, that PET signals were undetectable in other synucleinopathies despite the tracer binding post-mortem tissue from those same disorders.
Meanwhile the non-imaging competitor has already won the diagnostic question for Parkinson's. Seed amplification assays on cerebrospinal fluid are reported at 87.7% sensitivity and 96.3% specificity for Parkinson's in the PPMI cohort, with a pooled meta-analysis at 0.86 and 0.92. What the assay cannot do is say where in the brain the pathology is, or how much, or whether a drug reduced it, and it is markedly less reliable in multiple system atrophy. That is the residual space an imaging agent has.
There is no way to see pathological alpha-synuclein in a living brain, so ambiguous parkinsonian syndromes cannot be told apart at the molecular level and no anti-alpha-synuclein drug can demonstrate that it engaged its target.
- Lewy-type aggregate density in Parkinson's disease may simply be below what PET can resolve, in which case no affinity improvement rescues the indication.
- Without an approved anti-alpha-synuclein therapy there is no companion market, and the leading antibody missed its phase 2 primary endpoint.
- The cerebrospinal fluid assay is cheap, accurate for Parkinson's and already adopted in research, which caps what an imaging agent can claim.
- Any tracer reporting a measurable Parkinson's-versus-control difference in vivo, which is the single result that would change this record.
- Longitudinal multiple system atrophy studies with the current agent, which could establish a progression biomarker even without a Parkinson's claim.
- Anti-alpha-synuclein therapeutic readouts, since a companion agent needs a drug to accompany.
The five domains of a radiopharmaceutical due-diligence review, adapted from the Fryback-Thornbury hierarchy of diagnostic efficacy. Each carries the state of the public evidence and the fact behind it, not a score out of five: a single total hides the reason and stops telling candidates apart. Domains marked as carrying most weight are the ones that decide the case at this asset's stage.
Alpha-synuclein aggregation defines Parkinson's disease, dementia with Lewy bodies and multiple system atrophy, and the tracer binds post-mortem tissue from all of them; the in-vivo failure is one of aggregate density, not of target validity.
One published 42-participant cohort from one tracer, plus a completed phase 1; no agent has reached a pivotal or registrational trial and no FDA-approved alpha-synuclein PET agent exists.
Binding separates multiple system atrophy from controls and from other neurodegenerative disorders, but is limited in Parkinson's disease, which is the population that would generate most of the demand.
No serious safety signal has been reported in the small published cohorts, but no independently verified dosimetry table for the leading agent was found.
A precedent exists for approving an intracellular-aggregate PET agent: flortaucipir F-18 and the amyloid agents were approved on correspondence with pathology rather than on a treatment-selection claim.
Red, amber or green on each review category, each with its reason, so an obvious no-go takes seconds rather than a meeting.
The leading fluorine-18 tracer gives no detectable signal in Parkinson's disease in vivo despite binding the tissue post mortem; that is the whole technical problem and it is unsolved.
The diagnostic need is real but partly met: a cerebrospinal fluid assay reaches 87.7% sensitivity and 96.3% specificity for Parkinson's, leaving imaging the regional and pharmacodynamic questions.
The leading chemical series belongs to AC Immune; several academic and company programmes are chasing new scaffolds.
Companion-only in practice, and no anti-alpha-synuclein therapy is approved; prasinezumab did not separate from placebo on the primary endpoint of its phase 2.
Fluorine-18, the most distributable PET isotope.
Several groups are pursuing new scaffolds and the cerebrospinal fluid assay is already in wide research use, so a tracer must beat a cheap incumbent on a narrower question.
- AC Immune SA with Invicrophase 1 complete
[18F]ACI-12589 / [18F]MNI-1216, first-in-human complete, 42-participant published cohort; works in multiple system atrophy, limited in Parkinson's.
https://pmc.ncbi.nlm.nih.gov/articles/PMC10611796/ - Seed amplification assay developersin research and clinical use
Cerebrospinal fluid alpha-synuclein seed amplification, reported at 87.7% sensitivity and 96.3% specificity for Parkinson's in the PPMI cohort.
https://www.movementdisorders.org/MDS/Scientific-Issues/posts/The-past-present-and-future-roles-of-a-synuclein-seed-amplification-assays.htm
Similar pages
not linked directly; found by shared links- TargetDLG4 (PSD-95)
Shares Tau protein (neurofibrillary tangles), Amyloid beta plaques, PET (positron emission tomography) and the tag neurology.
- TrialA Study to Evaluate the Safety and Diagnostic Performance of F18 FBPA PET/CT Imaging in Solid Tumors
Shares PET (positron emission tomography), PET/CT, Fluorine-18.
- IndicationAlzheimer's disease
Shares Ioflupane I-123 and the tag neurology.
- OpportunityCXCR4 imaging instead of adrenal vein sampling
Shares PET (positron emission tomography), PET/CT and the tag unmet need first.
- TrialStudy of 18F-Florastamin PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer
Shares PET (positron emission tomography), PET/CT, Fluorine-18.
- OpportunityCEACAM5 imaging for occult colorectal recurrence
Shares PET/CT, Fluorine-18 and the tag unmet need first.
- AgentFluoroestradiol F-18 (FES PET)
Shares PET (positron emission tomography), PET/CT, Fluorine-18.
- OpportunityAn inflammation tracer that does not need a diet
Shares PET/CT, Fluorine-18 and the tag unmet need first.